Physician profile
Samuel Hopper
NPI 1265543623
$1,150.52
in general payments reported to CMS, 2019-2025
12 companies · $219 in 2025
The $219 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.52 · 2021: $92.92 · 2022: $204 · 2023: $423 · 2024: $183 · 2025: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $825.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $629.49 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Neurelis, INC. | $162.82 | 2022-2025 | Valtoco |
| Sumitomo Pharma America, INC. | $65.24 | 2023 | Aptiom |
| Jazz Pharmaceuticals INC. | $54.24 | 2025 | |
| Sk Life Science, INC. | $52.13 | 2024-2025 | |
| Lundbeck LLC | $42.39 | 2021 | |
| Eisai INC. | $32.73 | 2022 | |
| Pyros Pharmaceuticals, INC. | $29.62 | 2024 | Vigpoder |
| Greenwich Biosciences, INC. | $27.52 | 2019 | |
| Acadia Pharmaceuticals INC | $22.30 | 2023 | Daybue |
| Tris Pharma INC | $20.51 | 2025 | Dyanavel Xr |
| Zogenix INC. | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Hopper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.